Elevian and Insilico Medicine Collaborates to Develop Therapies Targeting Aging

 Elevian and Insilico Medicine Collaborates to Develop Therapies Targeting Aging
Shots:
  • Elevian collaborated with Insilico to develop and commercialize candidates targeting GDF11 pathway to treat
    age-related disorders
  • The collaboration focuses on the drug discovery and development using Insilico’s generative adversarial networks (GANs) and reinforcement learning (RL) AI technologies to the targets provided by Elevian targeting aging
  • GDF11 is a myostatin (GDF8)-homologous protein involved in inhibiting nerve tissue growth and further affecting cellular growth. Additionlaly, Insilico collaborated with Juvenescence Limited & Buck Institute for Research on Aging to discover candidates for for aging

Click here to read full press release/ article | Ref: BusinessWire | Image: Lifeboat


Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post